41202-32-8

Basic information

• Product Name: 1-(2-Chlorophenyl)piperazine hydrochloride
• Synonyms: TIMTEC-BB SBB003263;N-(2-CHLOROPHENYL)PIPERAZINE MONOHYDROCHLORIDE;LABOTEST-BB LT00159499;LABOTEST-BB LT00454957;1-(O-CHLOROPHENYL)PIPERAZINE HYDROCHLORIDE;1-(2-CHLOROPHENYL)PIPERAZINE HYDROCHLORIDE;1-(2-CHLOROPHENYL)PIPERAZINE MONOHYDROCHLORIDE;1-(2-chlorophenyl)piperazinium chloride
• CAS NO: 41202-32-8
• Molecular Formula: C₁₀H₁₃ClN₂*ClH
• Molecular Weight: 233.14
• EINECS: 255-262-0
• Product Categories: Piperidines, Piperidones, Piperazines;PiperazineDerivative;Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;Piperazines;PiperazinesHeterocyclic Building Blocks
• Mol File: 41202-32-8.mol
• Article Data: 6

Chemical Properties

• Melting Point: 160-163 °C (dec.)(lit.)
• Boiling Point: 317.4 °C at 760 mmHg
• Flash Point: 145.7 °C
• Appearance: /
• Vapor Pressure: 0.000387mmHg at 25°C
• Sensitive: Hygroscopic
• BRN: 5652889
• CAS DataBase Reference: 1-(2-Chlorophenyl)piperazine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-Chlorophenyl)piperazine hydrochloride(41202-32-8)
• EPA Substance Registry System: 1-(2-Chlorophenyl)piperazine hydrochloride(41202-32-8)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• WGK Germany: 3
• Hazardous Substances Data: 41202-32-8(Hazardous Substances Data)

Usage

General Description

1-(2-Chlorophenyl)piperazine hydrochloride, also known as 2-CPP hydrochloride, is a chemical compound known for its pharmacological properties. It is commonly used in scientific research as a component in the synthesis of various pharmaceuticals. 1-(2-Chlorophenyl)piperazine hydrochloride belongs to a group of chemicals known as phenylpiperazines, which are known for their diverse range of neurobiological effects. As a hydrochloride, this chemical is in a salt form, which typically increases its water solubility, making it suitable for experimental uses. However, as with many chemical agents, it should be handled with caution due to its potential toxicity and its ability to cause skin and eye irritation.

InChI:InChI=1/C10H13ClN2.ClH/c11-9-3-1-2-4-10(9)13-7-5-12-6-8-13;/h1-4,12H,5-8H2;1H

Upstream product

• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 
• 95-51-2 o-chloroaniline 
• 1104513-49-6 tert-butyl 4-(2-chlorophenyl)piperazine-1-carboxylate 

Downstream Products

• 110164-60-8 N-(2-carbomethoxythien-3-yl)-N'-[2-[4-(2-chlorophenyl)piperazin-1-yl]ethyl]urea 
• 114943-04-3 2-(3-{2-[4-(2-Chloro-phenyl)-piperazin-1-yl]-ethyl}-ureido)-thiophene-3-carboxylic acid ethyl ester 
• 95356-07-3 6-<2-<4-(2-chlorophenyl)-1-piperazinyl>ethyl>-5,6,7,8-tetrahydro-1,6-naphthyridine 
• 83100-05-4 6-{3-[4-(2-Chloro-phenyl)-piperazin-1-yl]-propyl}-5,6,7,8-tetrahydro-[1,6]naphthyridine 
• 95395-61-2 6-<2-<4-(2-chlorophenyl)-1-piperazinyl>ethyl>-5,6,7,8-tetrahydro-1,6-naphthyridine difumarate 
• 83100-06-5 6-{3-[4-(2-Chloro-phenyl)-piperazin-1-yl]-propyl}-5,6,7,8-tetrahydro-[1,6]naphthyridine; compound with (E)-but-2-enedioic acid 
• 212143-81-2 2-Bromo-3-[4-(2-chloro-phenyl)-piperazin-1-ylmethyl]-6H-imidazo[1,2-c]quinazolin-5-one 
• 212143-89-0 2-Bromo-3-[4-(2-chloro-phenyl)-piperazin-1-ylmethyl]-thiazolo[2,3-b]quinazolin-5-one 
• 212143-70-9 3-Bromo-2-[4-(2-chloro-phenyl)-piperazin-1-ylmethyl]-6H-imidazo[1,2-c]quinazolin-5-one 
• 22662-15-3 3-[4-(2-chloro-phenyl)-piperazin-1-yl]-1-phenyl-propan-1-one 
• 475596-09-9 1-[(1,2-diphenyl-1H-imidazol-4-yl)carbonyl]-4-(2-chlorophenyl)piperazine 
• 870126-89-9 N-carbamimidoyl-4-(2-chlorophenyl)piperazine-1-carboximidic acid amide 

Relevant articles and documents

Preparation method of diaryl sulfide amine compound

The invention relates to a preparation method for a diaryl thioether amine compound. Specifically, the invention relates to a preparation method for 1-[2-(2,4-dimethylphenylsulfalkyl)phenyl]piperazine derivative as shown in a formula I which is described in the specification. The preparation method comprises the following steps: subjecting a compound as shown in a formula V and a compound as shown in a formula IV to cyclization, condensation or introduction of an amino protective group; carrying out further condensation; etc. Thus, the target compound is obtained. Compared with other methods, the preparation method provided by the invention has the advantages of good process reproducibility and easy operation and the characteristics of high yield, low cost and high product purity, is more suitable for industrial production and has higher economic benefits.

Design, synthesis, and evaluation of bitopic arylpiperazine-phthalimides as selective dopamine D3 receptor agonists

The dopamine D3 receptor (D3R) is a proven therapeutic target for the treatment of neurological and neuropsychiatric disorders. In particular, D3R-selective ligands that can eliminate side effects associated with dopamine D2 receptor (D2R) therapeutics have been validated. However, the high homology in signaling pathways and the sequence similarity between D2R and D3R have rendered the development of D3R-selective ligands challenging. Herein, we designed and synthesized a series of piperazine-phthalimide bitopic ligands based on a fragment-based and molecular docking inspired design. Compound 9i was identified as the most selective D3R ligand among these bitopic ligands. Its selectivity was improved compared to reference compounds 1 and 2 by 9- and 2-fold, respectively, and it was 21-fold more potent than compound 2. Molecular docking demonstrated that the orientation of Leu2.64 and Phe7.39 and the packing at the junction of helices may affect the specificity for D3R over D2R. Functional evaluation revealed that D3R-selective ligand 9i displayed a subpicomolar agonist activity at D3R with a 199-fold increase in potency compared to quinpirole. These results may be useful for the fragment-based design of bitopic compounds as selective D3R ligands.

Exploration of substituted arylpiperazine–tetrazoles as promising dual norepinephrine and dopamine reuptake inhibitors

In the search for potent dual norepinephrine and dopamine reuptake inhibitors, several substituted arylpiperazine–tetrazoles were designed, synthesized and evaluated for their neurotransmitter reuptake inhibitory activities. Various derivatives exhibited selective and strong neurotransmitter reuptake inhibitory activity. In particular, compounds with a three-carbon linker displayed selective and stronger potency than those with two-carbon and four-carbon linkers. Interestingly, six compounds, 9b, 9c, 9d, 9o, 9q and 9u displayed more effective activity than the standard drug, bupropion. The provided SAR data and potent biological activity can offer useful guidelines for designing dual norepinephrine and dopamine reuptake inhibitors as effective therapeutic agents for treatment of several central nervous system diseases.